Modulation and source of procalcitonin in reduced renal function and renal replacement therapy

Scandinavian Journal of Immunology

Volumn 61, Issue 2, 2005, Pages 180-186

  Herget Rosenthal, S ^a   Klein, T ^a   Marggraf, G ^a   Hirsch, T ^a   Jakob, H G ^a   Philipp, T ^a   Kribben, A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OLIGURIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SYNTHESIS;

C-REACTIVE PROTEIN; CALCITONIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROTEIN PRECURSORS; STATISTICS, NONPARAMETRIC;

EID: 13844276265     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2005.01545.x     Document Type: Article

References (40)

1. Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001;86:396-404.
2. Russwurm S, Stonans I, Stonane E et al. Procalcitonin and CGRP-I mRNA expression in various human tissues. Shock 2001;16:109-12.
3. Whang KT, Steinwald PM, White JC et al. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998;83:3296-301.
4. Wanner GA, Keel M, Steckholzer U, Beier W, Stocker R, Ertel W. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000;28:950-7.
5. Christ-Grain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 2004;363:600-7.
6. Castelli GP, Pognani C, Meisner M et al. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004;8:R234-R242.
7. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31:1737-41.
8. Oberhoffer M, Stonans I, Russwurm S et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999;134:49-55.
9. Balog A, Ocsovszki I, Mandi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett 2002;84:199-203.
10. Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med 2002;30:2091-5.
11. Wagner KE, Martinez JM, Vath SD et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 2002;30:2313-21.
12. Wiedermann FJ, Kaneider N, Egger P et al. Migration of human monocytes in response to procalcitonin. Crit Care Med 2002;30:1112-7.
13. Monneret G, Arpin M, Venet F et al. Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils. Intensive Care Med 2003;29:923-8.
14. Herget-Rosenthal S, Marggraf G, Pietruck F et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 2001;16:975-9.
15. Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 2002;15:297-301.
16. Schmidt M, Burchardi C, Sitter T, Held E, Schiffl H. Procalcitonin in patients undergoing chronic hemodialysis. Nephron 2000;84:187-8.
17. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease and invasive bacterial infection. Arthritis Rheum 1997;40:1250-6.
18. Level C, Chauveau P, Delmas Y et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant 2001;16:980-6.
19. Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003;29:579-83.
20. Kylanpa-Back ML, Takala A, Kemppainen EA et al. Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis. Crit Care Med 2001;29:63-9.
21. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998;24:680-4.
22. Oberhoffer M, Vogelsang H, Jager L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care 1999;14:29-33.
23. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Muller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004;32:1715-21.
24. Levey AS, Coresh J, Balk E et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
25. Preas HL, Nylen ES, Snider RH et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis 2001;184:373-6.
26. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-58.
27. Meisner M, Lohs T, Huertemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rare and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 2001;18:79-87.
28. Descamps-Latscha B, Jungers P, Witko-Sarsar V. Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 2002;20:481-4.
29. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329-37.
30. Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.
31. Sniveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003;63:654-61.
32. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
33. Herbelin A, Nguyen AT, Zingraff J, Urena P, Deschamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 1990;37:116-25.
34. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-6.
35. Linscheid P, Seboek D, Nylen ES et al. In vitro and in vivo calcitonin-I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003;144:5578-84.
36. Nijsten MW, Olinga P, The TH et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000;28:458-61.
37. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-9.
38. Chauveau P, Level C, Lasseur C et al. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study. J Ren Nutr 2003;13:137-43.
39. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;101:1767-72.
40. Oldamaki M, Kato A, Kumagai H, Hishida A. Counter-regulatory effects of procalcitonin and indoxyl sulphate on net albumin secretion by cultured rat hepatocytes. Nephrol Dial Transplant 2004;19:797-804.